UK markets closed
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • FTSE 250

    22,263.24
    -451.74 (-1.99%)
     
  • AIM

    1,132.08
    -24.37 (-2.11%)
     
  • GBP/EUR

    1.1942
    -0.0077 (-0.64%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.33%)
     
  • BTC-GBP

    25,846.47
    -1,308.22 (-4.82%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.02 (-1.30%)
     
  • CRUDE OIL

    86.29
    -0.61 (-0.70%)
     
  • GOLD FUTURES

    1,836.10
    -6.50 (-0.35%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     
  • HANG SENG

    24,965.55
    +13.20 (+0.05%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • CAC 40

    7,068.59
    -125.57 (-1.75%)
     

LENSAR Announces Poster Presentations at the American Academy of Ophthalmology

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • LNSR

Demonstrates LENSAR Laser’s Ability to Guide Improved Astigmatic Outcomes for Patients

ORLANDO, Fla., November 12, 2021--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that two posters have been accepted for virtual presentation at the Annual Meeting of the American Academy of Ophthalmology (AAO) being held November 12-15, 2021.

The titled presentations will be available on the AAO meeting portal starting on November 12, 2021:

Femtosecond Laser Image Guided Corneal Arcuate Incisions for Managing Mild Keratometric Astigmatism in Cataract Surgery, by Denise Visco, M.D.

Toric IOL alignment with femtosecond laser capsular marks confirmed by intraoperative aberrometry, by Dee Stephenson, M.D.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005371/en/

Contacts

Thomas R. Staab, II, CFO
ir.contact@lensar.com

Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting